-- The NEW Official Alizyme Thread! --

I'd like to tip Sensibilia Plc. (LSE:SENB) Currently 0.5p. A cutting edge techno-biotech, it is a definite Quintuple bagger in January 2006.

SENB combine the best of Biotechnology with a 22nd century virtual delivery system. Their lead product is CetiliTwat. When delivered over the Internet, this drug, currently in Phase 4, leaps out of the computer monitor and batters QAZWSX123 to a painful death. Although having a necessarily limited potential market, it is feted by many as a blockbuster product. A takeover is mooted at 25, 50, 200 and 2500p. BUY.